ArticleScientific reports2019
Tumor necrosis factor induces rapid down-regulation of TXNIP in human T cells.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 29 citations in OpenAlex.
- Teplizumab induces persistent changes in the antigen-specific repertoire in individuals at risk for type 1 diabetes.The Journal of clinical investigation · 2024Trial
- Acetylation reader BRD4-driven TXNIP transcription enhances NLRP3 inflammasome activation in PCOS.Cellular and molecular life sciences : CMLS · 2025Article
- Single-Cell Sequencing Reveals Novel Tumor Populations and Their Interplay with the Immune Microenvironment in a Pleomorphic Rhabdomyosarcoma.International journal of molecular sciences · 2025Article
- Adipocyte/Tumor cell crosstalk via IGF-1/TXNIP axis promotes malignancy and endocrine resistance in breast cancer.Cell communication and signaling : CCS · 2025Article
- Article
- TET2-mediated 5-hydroxymethylcytosine of TXNIP promotes cell cycle arrest in systemic anaplastic large cell lymphoma.Clinical epigenetics · 2025Article
- Glucose deprivation and identification of TXNIP as an immunometabolic modulator of T cell activation in cancer.Frontiers in immunology · 2025Article
- Up-Regulated Expression of Thioredoxin-Interacting Protein (TXNIP) in Mesenchymal Stem Cells Associated with Severe Aplastic Anemia in Children.International journal of molecular sciences · 2024Article
- The role of TXNIP in cancer: a fine balance between redox, metabolic, and immunological tumor control.British journal of cancer · 2023Review
- Functional interrogation of lymphocyte subsets in alopecia areata using single-cell RNA sequencing.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- The regenerative response of cardiac interstitial cells.Journal of molecular cell biology · 2023Article
- Differential Expression Enrichment Tool (DEET): an interactive atlas of human differential gene expression.NAR genomics and bioinformatics · 2023Article
- Article
- Immunomodulatory Role of Thioredoxin Interacting Protein in Cancer's Impediments: Current Understanding and Therapeutic Implications.Vaccines · 2022Review
- Article
- Macrophages Control the Bioavailability of Vitamin D and Vitamin D-Regulated T Cell Responses.Frontiers in immunology · 2021Article
- Impaired Vitamin D Signaling in T Cells From a Family With Hereditary Vitamin D Resistant Rickets.Frontiers in immunology · 2021Article
- Article
- Thioredoxin activity confers resistance against oxidative stress in tumor-infiltrating NK cells.The Journal of clinical investigation · 2020Article
- MicroRNA-106b Regulates Expression of the Tumour Suppressors p21 and TXNIP and Promotes Tumour Cell Proliferation in Mycosis Fungoides.Acta dermato-venereologica · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In addition to antigen-driven signals, T cells need co-stimulatory signals for robust activation. Several receptors, including members of the tumor necrosis factor receptor superfamily (TNFRSF), can deliver co-stimulatory signals to T cells. Thioredoxin interacting protein (TXNIP) is an important inhibitor of glucose uptake and cell proliferation, but it is unknown how TXNIP is regulated in T cells. The aim of this study was to determine expression levels and regulation of TXNIP in human T cells. We found that naïve T cells express high levels of TXNIP and that treatment of blood samples with TNF results in rapid down-regulation of TXNIP in the T cells. TNF-induced TXNIP down-regulation correlated with increased glucose uptake. Furthermore, we found that density gradient centrifugation (DGC) induced down-regulation of TXNIP. We demonstrate that DGC induced TNF production that paralleled the TXNIP down-regulation. Treatment of blood with toll-like receptor (TLR) ligands induced TNF production and TXNIP down-regulation, suggesting that damage-associated molecular patterns (DAMPs), such as endogenous TLR ligands, released during DGC play a role in DGC-induced TXNIP down-regulation. Finally, we demonstrate that TNF-induced TXNIP down-regulation is dependent on caspase activity and is caused by caspase-mediated cleavage of TXNIP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.